CORTESI, LAURA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 17.010
AS - Asia 6.879
EU - Europa 5.861
SA - Sud America 1.038
Continente sconosciuto - Info sul continente non disponibili 433
AF - Africa 213
OC - Oceania 49
Totale 31.483
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 16.595
SG - Singapore 2.069
IT - Italia 1.725
CN - Cina 1.568
GB - Regno Unito 1.338
VN - Vietnam 804
HK - Hong Kong 800
BR - Brasile 766
DE - Germania 555
SE - Svezia 551
BD - Bangladesh 457
FI - Finlandia 304
RU - Federazione Russa 288
FR - Francia 248
CA - Canada 204
UA - Ucraina 195
KR - Corea 177
TR - Turchia 168
IN - India 164
ID - Indonesia 151
IE - Irlanda 117
BG - Bulgaria 96
MX - Messico 83
AR - Argentina 80
NL - Olanda 72
JP - Giappone 69
ZA - Sudafrica 64
IQ - Iraq 60
PL - Polonia 56
PK - Pakistan 48
AU - Australia 45
EC - Ecuador 45
BE - Belgio 44
MY - Malesia 44
AT - Austria 43
ES - Italia 42
AE - Emirati Arabi Uniti 41
SA - Arabia Saudita 39
CO - Colombia 37
MA - Marocco 37
VE - Venezuela 34
PH - Filippine 28
UZ - Uzbekistan 27
CL - Cile 26
LT - Lituania 26
EG - Egitto 22
PY - Paraguay 22
JM - Giamaica 21
CR - Costa Rica 20
IR - Iran 19
KE - Kenya 19
CH - Svizzera 17
RO - Romania 16
TH - Thailandia 16
TN - Tunisia 16
JO - Giordania 15
NP - Nepal 15
GR - Grecia 14
SI - Slovenia 14
TW - Taiwan 13
AZ - Azerbaigian 12
CZ - Repubblica Ceca 12
BZ - Belize 11
DZ - Algeria 11
HN - Honduras 11
IL - Israele 11
RS - Serbia 11
PE - Perù 10
PT - Portogallo 10
SY - Repubblica araba siriana 10
TT - Trinidad e Tobago 10
DO - Repubblica Dominicana 9
HU - Ungheria 9
NO - Norvegia 9
PA - Panama 9
AL - Albania 8
BO - Bolivia 8
GT - Guatemala 8
LV - Lettonia 8
NI - Nicaragua 8
SC - Seychelles 8
UY - Uruguay 8
GE - Georgia 7
SV - El Salvador 7
BY - Bielorussia 6
LB - Libano 6
OM - Oman 6
KZ - Kazakistan 5
PS - Palestinian Territory 5
AO - Angola 4
BB - Barbados 4
DK - Danimarca 4
EE - Estonia 4
ET - Etiopia 4
EU - Europa 4
HR - Croazia 4
KG - Kirghizistan 4
MD - Moldavia 4
MK - Macedonia 4
SN - Senegal 4
Totale 30.986
Salva come PNG Salva come JPEG
Città #
Ashburn 1.994
Fairfield 1.371
Santa Clara 1.333
Singapore 1.234
San Jose 968
Council Bluffs 861
Hong Kong 777
Woodbridge 747
Southend 735
Chandler 708
Houston 605
Seattle 551
Cambridge 488
Wilmington 445
Hefei 436
Beijing 332
Nyköping 317
Los Angeles 313
Ann Arbor 307
Dearborn 302
London 289
Jacksonville 288
Milan 269
New York 261
Ho Chi Minh City 245
Chicago 223
Helsinki 221
Hanoi 185
Modena 167
Dallas 161
Seoul 161
The Dalles 154
San Diego 135
Jakarta 118
Dublin 115
Lauterbourg 113
Princeton 100
Sofia 93
Izmir 89
Salt Lake City 89
Buffalo 87
Moscow 82
Munich 80
Rome 77
Columbus 75
Boardman 74
Bologna 73
Eugene 70
Phoenix 69
Shanghai 67
São Paulo 67
Orem 64
Bremen 63
Tokyo 57
Frankfurt am Main 54
Atlanta 47
Brooklyn 46
Montreal 45
Elk Grove Village 43
Dong Ket 39
Haiphong 38
Toronto 38
Warsaw 38
Miami 37
Miano 36
Redwood City 34
Da Nang 32
Denver 32
Florence 31
Chennai 30
Mexico City 30
Brussels 29
Johannesburg 29
Falls Church 28
Fremont 27
Las Vegas 27
Tampa 27
Franklin 26
Belo Horizonte 25
Philadelphia 25
Turku 25
Reading 24
Sterling 24
Des Moines 23
Vienna 23
Amsterdam 22
Naples 22
Reggio Emilia 22
Stockholm 22
Nuremberg 21
Boston 20
Guangzhou 20
Parma 20
Portsmouth 20
Rio de Janeiro 20
Tashkent 20
Baghdad 19
Brasília 19
Kent 19
Ottawa 19
Totale 20.622
Salva come PNG Salva come JPEG
Nome #
The italian multi-center project on evaluation of MRI and other imaging modalities in early detection of breast cancer in subjects at high genetic risk 580
A rapid genetic counselling and testing in newly diagnosed breast cancer is associated with high rate of risk-reducing mastectomy in BRCA1/2-positive italian women 489
Neoadjuvant treatments in triple-negative breast cancer patients: where we are now and where we are going 409
Differential molecular pathways expression in HER2 positive early breast cancer according to hormone receptor status. 403
Prognosis and treatment of micrometastatic breast cancer sentinel lymph node: a population-based study. 401
Penetrances of breast and ovarian cancer in a large series of families tested for BRCA1/2 mutations 398
Identification of protein clusters predictive of response to chemotherapy in breast cancer patients 396
Protein expression patterns associated with advanced stage ovarian cancer 386
Hereditary pancreatic cancer: A retrospective single-center study of 5143 Italian families with history of BRCA-related malignancies 376
Elongation factor 1 alpha interacts with phospho-Akt in breast cancer cells and regulates their proliferation, survival and motility 376
Genomic alterations at the basis of treatment resistance in metastatic breast cancer: Clinical applications 375
Breast cancer screening in women at increased risk according to different family histories: an update of the Modena Study Group experience 371
Collective evidence supports neutrality of BRCA1 V1687I, a novel sequence variant in the conserved THV motif of the first BRCT repeat 367
Double heterozygosity for BRCA1 and hMLH1 gene mutations in a 46-year-old woman with five primary tumors 362
Italian family with two independent mutations:3358T/A in BRCA1 and 8756delA in BRCA2 genes. 361
A novel deletion of BRCA1 gene that eliminates the ATG initiation codon without affecting the promoter region 359
Ovarian cancer: can proteomics give new insights for therapy and diagnosis? 354
Molecular mechanisms of PARP inhibitors In BRCA-related ovarian cancer 342
Favourable ten-year overall survival in a Caucasian population with high probability of hereditary breast cancer. 333
Clinical and molecular predictors of long-term response in HER2 positive metastatic breast cancer patients. 330
CHIRURGIA PROFILATTICA DELLA MAMMELLA NELLE PAZIENTI PORTATRICI DI MUTAZIONE DEL GENE BRCA 1/2. PERCORSO DIAGNOSTICO-TERAPEUTICO. 326
A case of skeletal and bone marrow metastases from breast cancer treated with eribulin mesylate 320
Prophylactic Surgery to Reduce the Risk of Developing Breast Cancer: Issues and Clinical Implications 314
MRI in high risk women: benefits and problems 312
Risk of second primary malignancy in breast cancer survivors: A nested population-based case-control study 311
Combined Hormonal Contraceptive Use and Risk of Breast Cancer in a Population of Women With a Family History 307
Usefulness and limitations of comprehensive characterization of mRNA splicing profiles in the definition of the clinical relevance of BRCA1/2 variants of uncertain significance 306
Identification of families with hereditary breast and ovarian cancer for clinical and mammographic surveillance: the Modena Study Group proposal 305
Hereditary Ovarian Cancer: Not Only BRCA 1 and 2 Genes 303
Predictive factors for relapse in triple-negative breast cancer patients without pathological complete response after neoadjuvant chemotherapy 302
Clinicopathologic Profile of Breast Cancer in Germline ATM and CHEK2 Mutation Carriers 302
Tumor size, node status, grading, HER2 and estrogen receptor status still retain a strong value in patients with operable breast cancer diagnosed in recent years. 301
MRI before initial surgery outside of clinical trials: the real world! 301
Evaluation of Transvaginal Ultrasound plus CA-125 Measurement and Prophylactic Salpingo-Oophorectomy in Women at Different Risk Levels of Ovarian Cancer: The Modena Study Group Cohort Study 300
An oncologist-based model of cancer genetic counselling for hereditary breast and ovarian cancer 299
Reproductive risk factors in women with family history of breast cancer attending an Italian Family Cancer Clinic 298
Multicenter comparative multimodality surveillance of women at genetic-familial risk for breast cancer (HIBCRIT study): interim results. 296
Molecular Biomarkers for Prediction of Targeted Therapy Response in Metastatic Breast Cancer: Trick or Treat? 293
Different expressivity of BRCA1 and BRCA2: analysis of 179 Italian pedigrees with identified mutation 289
FANCM c.5791C>T nonsense mutation (rs144567652) induces exon skipping, affects DNA repair activity and is a familial breast cancer risk factor 289
The Association between Endometriomas and Ovarian Cancer: Preventive Effect of Inhibiting Ovulation and Menstruation during Reproductive Life 288
BRCA1 mutations and clinico-pathological features in a sample of italian women with early-onset breast cancer 287
Two-month stop in mammographic screening significantly impacts on breast cancer stage at diagnosis and upfront treatment in the COVID era 282
Distribution of second primari malignancies suggest a bidirectional effect between breast and endometrial cancer. A population-based study 279
Breast ultrasonography (BU) in the screening protocol for women at hereditary-familial risk of breast cancer: has the time come to rethink the role of BU according to different risk categories? 278
Acceptability and adherence in a chemoprevention trial among women at increased risk for breast cancer attending the modena familial breast and ovarian cancer center (Italy) 277
Prognosis of screen-detected breast cancers: results of a population based study 277
Comparison between genotype and phenotype identifies a high-risk population carryingBRCA1 mutations 273
Increased incidence of breast cancer in postmenopausal women with high body mass index at the modena screening program 270
A regional population-based hereditary breast cancer screening tool in Italy: First 5-year results 269
STRATEGIES TO PREDICT TREATMENT RESPONSE AND SELECT THERAPIES IN METASTATIC BREAST CANCER PATIENTS USING A NEXT GENERATION SEQUENCING MULTI-GENE PANEL 262
Hereditary risk of breast cancer: not only brca 259
Clinical and Pathological Features of Breast Cancer in Systemic Sclerosis: Results from the Sclero-Breast Study 258
Outcome evaluation in pre-trastuzumab era between different breast cancer phenotypes: a population-based study on italian women 257
Comment on "Cancer genetic counselling' by P.!Mandich et al. (Ann Oncol 2005; 16: 171) 256
Characterization of new ATM deletion associated with hereditary breast cancer 255
The impact of reproductive life on breast cancer risk in women with family history or BRCA mutation 254
Spatial Distribution of Immune Cells Drives Resistance to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer 253
Chemoprevention strategies for high risk women 251
Prediction of breast and prostate cancer risks in male BRCA1 and BRCA2 mutation carriers using polygenic risk scores 249
Large scale multifactorial likelihood quantitative analysis of BRCA1 and BRCA2 variants: An ENIGMA resource to support clinical variant classification 247
Chemoprevention strategies in hereditary breast and ovarian cancer syndromes 246
Twenty-years experience with de novo metastatic breast cancer 246
Male Bilateral Risk-Reducing Mastectomy: Report of a Case 243
Radiological screening programs for women at high risk of developing breast cancer 241
BRCA mutations among triple negative breast cancer without family history of breast and ovarian cancer: The Modena family cancer clinic experience 241
Indications for breast magnetic resonance imaging. Consensus Document "Attualità in Senologia", Florence 2007 237
Automated capture-based NGS workflow: one thousand patients experience in a clinical routine framework 237
Usefulness of breast MRI in a patient with genetic risk 236
Evaluation of widely used models for predicting BRCA1 and BRCA2 mutations 230
Prevalence of BRCA1 genomic rearrangements in a large cohort of Italian breast and breast/ovarian cancer families without detectable BRCA1 and BRCA2 point mutations 229
Breast ultrasound in high-risk women 227
Association of genomic domains in BRCA1 and BRCA2 with prostate cancer risk and aggressiveness 223
Satisfaction with prophylactic risk-reducing salpingo-oophorectomy in BRCA mutation carriers is very high and little dependent on the participants' characteristics at surgery: a prospective study 220
Exceptional response to lurbinectedin and irinotecan in BRCA-mutated platinum-resistant ovarian cancer patient: a case report 219
BRCA mutation carriers' perceptions on postmenopausal hormone therapy: An Italian study 218
Implementation of preventive and predictive BRCA testing in patients with breast, ovarian, pancreatic, and prostate cancer: a position paper of Italian Scientific Societies 216
Molecular Pathways of Breast Cancer in Systemic Sclerosis: Exploratory Immunohistochemical Analysis from the Sclero-Breast Study 213
The reduction of CA 125 serum levels in BRCA 1/2 mutation carriers after risk-reducing salpingo-oophorectomy is only partially associated with surgery: A prospective cohort, other biomarker controlled, study 213
Multicenter surveillance of women at high genetic breast cancer risk using mammography, ultrasonography, and contrast-enhanced magnetic resonance imaging (the high breast cancer risk italian 1 study): final results. 210
Changes in breast cancer incidence and stage distribution in Modena, Italy: the effect of mammographic screening program. 208
Thromboembolism and Adjuvant Endocrine Therapy (AET) in Hormone Receptor-Positive Early Breast Cancer (EBC): Did Treatment Evolution Change Incidence of the Adverse Event? A Meta-Analysis 203
Management of PALB2-associated breast cancer: A literature review and case report 201
Personalized Systemic Therapies in Hereditary Cancer Syndromes 200
Adjuvant Endocrine Therapy in Premenopausal Women With Hormone Receptor-Positive Early-Stage Breast Cancer: Risk Stratification in a Real-World Setting 197
Obesity in Postmenopausal Breast Cancer Patients: It Is Time to Improve Actions for a Healthier Lifestyle. The Results of a Comparison Between Two Italian Regions With Different “Presumed” Lifestyles 197
Primary fallopian tube carcinoma (PFTC) in a BRIP-1 mutation carrier: the first case report 191
Constitutional Mosaicism: A Critical Issue in the Definition of BRCA-Inherited Cancer Risk 190
The challenging screen detection of ovarian cancer in BRCA mutation carriers adhering to a 6-month follow-up program: results from a 6-years surveillance 183
DCE-MRI Radiomic analysis in triple negative ductal invasive breast cancer. Comparison between BRCA and not BRCA mutated patients: Preliminary results 180
BRCA mutation rate and characteristics of prostate tumor in breast and ovarian cancer families: analysis of 6,591 Italian pedigrees 176
Breast and Prostate Cancer Risks for Male BRCA1 and BRCA2 Pathogenic Variant Carriers Using Polygenic Risk Scores 176
The spectrum of fancm protein truncating variants in European breast cancer cases 167
Automation of a capture-based NGS workflow: one thousand patients experience in a diagnostic clinical routine framework 165
Parp-inhibitors in the therapeutic landscape of breast cancer patients with BRCA1 and BRCA2 pathogenic germline variants: An Italian consensus paper and critical review 162
Detection of germline variants in 450 breast/ovarian cancer families with a multi‐gene panel including coding and regulatory regions 162
A phase II study of pembrolizumab plus carboplatin in BRCA-related metastatic breast cancer (PEMBRACA) 161
Breast cancer screening of mutation carriers in the era of COVID-19 pandemic 159
La predisposizione genetica al cancro dell'ovaio. Individuazione e sorveglianza delle donne a rischio 155
Prophylactic risk-reducing salpingo-oophorectomy in BRCA mutation carriers: what is going on in a region of northern Italy? 152
Totale 27.353
Salva come PNG Salva come JPEG
Categoria #
all - tutte 132.445
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 132.445
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.719 0 0 238 90 55 129 117 108 229 165 368 220
2022/20232.135 263 280 137 198 242 257 41 185 332 26 81 93
2023/20241.480 89 77 104 141 239 128 179 178 41 45 78 181
2024/20254.955 146 40 110 287 913 718 445 290 554 210 532 710
2025/202611.047 715 341 766 1.058 1.440 634 1.128 491 1.006 997 1.572 899
2026/20272.604 698 1.242 664 0 0 0 0 0 0 0 0 0
Totale 31.483